Vanguard Group
SYRS

Vanguard Group’s Syros Pharmaceuticals, Inc. Common Stock SYRS Stock Holding History

Vanguard Group’s Portfolio SYRS Stock Details SYRS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-268,154
Closed -$61.7K – 4312
2024
Q4 		$61.7K Sell
268,154
-685,159
-72% -$822K ﹤0.01% 4197
2024
Q3 		$2.05M Sell
953,313
-14,904
-2% -$53.5K ﹤0.01% 3551
2024
Q2 		$5M Buy
968,217
+40,171
+4% +$211K ﹤0.01% 3264
2024
Q1 		$4.97M Buy
928,046
+163,234
+21% +$1.13M ﹤0.01% 3304
2023
Q4 		$5.96M Buy
764,812
+236,620
+45% +$810K ﹤0.01% 3210
2023
Q3 		$2.09M Buy
528,192
+30,984
+6% +$116K ﹤0.01% 3566
2023
Q2 		$1.57M Buy
497,208
+9,986
+2% +$32.1K ﹤0.01% 3745
2023
Q1 		$1.3M Buy
487,222
+14,492
+3% +$56.2K ﹤0.01% 3834
2022
Q4 		$1.7M Sell
472,730
-14,803
-3% -$64.2K ﹤0.01% 3721
2022
Q3 		$3.14M Buy
487,533
+199,272
+69% +$1.62M ﹤0.01% 3563
2022
Q2 		$2.77M Buy
288,261
+62,708
+28% +$587K ﹤0.01% 3664
2022
Q1 		$2.69M Sell
225,553
-53,484
-19% -$957K ﹤0.01% 3829
2021
Q4 		$9.1M Sell
279,037
-19,561
-7% -$792K ﹤0.01% 3276
2021
Q3 		$13.3M Buy
298,598
+21,040
+8% +$1.03M ﹤0.01% 3082
2021
Q2 		$15.1M Buy
277,558
+4,316
+2% +$255K ﹤0.01% 2991
2021
Q1 		$20.4M Buy
273,242
+68,772
+34% +$7.14M ﹤0.01% 2775
2020
Q4 		$22.2M Buy
204,470
+1,128
+0.6% +$103K ﹤0.01% 2587
2020
Q3 		$18M Buy
203,342
+13,205
+7% +$1.5M ﹤0.01% 2515
2020
Q2 		$20.3M Buy
190,137
+10,300
+6% +$925K ﹤0.01% 2420
2020
Q1 		$10.7M Buy
179,837
+127
+0.1% +$8.62K ﹤0.01% 2587
2019
Q4 		$12.4M Buy
179,710
+141
+0.1% +$8.55K ﹤0.01% 2753
2019
Q3 		$18.6M Buy
179,569
+3,068
+2% +$290K ﹤0.01% 2522
2019
Q2 		$16.3M Buy
176,501
+86,307
+96% +$6.01M ﹤0.01% 2615
2019
Q1 		$8.24M Buy
90,194
+22,180
+33% +$1.54M ﹤0.01% 2925
2018
Q4 		$3.79M Sell
68,014
-36,480
-35% -$2.77M ﹤0.01% 3179
2018
Q3 		$12.4M Buy
104,494
+4,356
+4% +$505K ﹤0.01% 2808
2018
Q2 		$10.2M Buy
100,138
+8,212
+9% +$1.02M ﹤0.01% 2894
2018
Q1 		$11.9M Buy
91,926
+33,676
+58% +$3.68M ﹤0.01% 2739
2017
Q4 		$5.67M Buy
58,250
+3,252
+6% +$437K ﹤0.01% 3083
2017
Q3 		$8.1M Buy
54,998
+16,738
+44% +$3.15M ﹤0.01% 2910
2017
Q2 		$6.16M Buy
38,260
+25,050
+190% +$3.94M ﹤0.01% 3010
2017
Q1 		$2.1M Buy
13,210
+9,673
+273% +$1.18M ﹤0.01% 3367
2016
Q4 		$430K Buy
3,537
+1,994
+129% +$280K ﹤0.01% 3761
2016
Q3 		$214K Buy
+1,543
New +$196K ﹤0.01% 3891

Other funds holding SYRS

Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
BBA
Baader Bank Aktiengesellschaft Unterschleissheim, Germany $1.33B AUM 47.35% 1-Year Est. Return
1CM
1492 Capital Management Milwaukee, Wisconsin $263M AUM 61.9% 1-Year Est. Return
XT
XTX Topco George Town, Cayman Islands $5.75B AUM 30.56% 1-Year Est. Return

Vanguard Group's SYRS Position: Q1 2025 in Review

Vanguard Group sold out of Syros Pharmaceuticals, Inc. Common Stock (SYRS) in Q1 2025, closing a stake of 268,154 shares — an estimated $61.7K sold.

Vanguard Group first reported a position in SYRS in Q3 2016 and held it in 34 quarters. The position peaked at $22.2M in Q4 2020. 7 funds tracked by Wall St. Rank hold SYRS as of Q1 2025.

  • Vanguard Group reported no remaining Syros Pharmaceuticals, Inc. Common Stock position as of Q1 2025 after selling out during the quarter.
  • Vanguard Group sold 268,154 Syros Pharmaceuticals, Inc. Common Stock shares in Q1 2025, an estimated $61.7K.
  • Vanguard Group first reported a position in Syros Pharmaceuticals, Inc. Common Stock in Q3 2016 and held it in 34 quarters.
  • Vanguard Group's Syros Pharmaceuticals, Inc. Common Stock position peaked at $22.2M in Q4 2020.
  • 7 funds tracked by Wall St. Rank held Syros Pharmaceuticals, Inc. Common Stock as of Q1 2025.

Based on Vanguard Group's 13F filing for Q1 2025, filed 9 May 2025.